semaglutide medicare price reduction announces cuts for Ozempic and other prescription drugs Medicare Coverage of Novo's Semaglutide

On March 2, 2023 and June 16, 2023 Lexaria announced that in pre-clinical diabetes study DIAB-A22-1 in obese diabetic-conditioned animals, DehydraTECH-CBD achieved each of the following: Lowered blood glucose levels by 19.9% (p0.05) Lowered overall body weight by 7% sustained over 8 weeks Increased locomotor activity (p0.05) Lowered triglyceride levels by more than 25% (p0.007) Lowered blood urea nitrogen levels by 27.9% (p0.001) On August 2, 2023 Lexaria announced its intention to study weight loss and diabetes control in a human population using DehydraTECH-CBD

In October, the case count reached 1,090, which increased to 1,221 by November, with 131 new cases filed

Pricing for the treatment will depend on dosing and market pricing

We saw this back in 2023 with the landmark A4 trial with solanezumab